Cochlear Ltd
ASX:COH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
258.7
350.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cochlear Ltd
Cochlear Ltd
Net Issuance of Common Stock
Cochlear Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cochlear Ltd
ASX:COH
|
Net Issuance of Common Stock
-AU$45.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Respiri Ltd
ASX:RSH
|
Net Issuance of Common Stock
AU$8.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-6%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Net Issuance of Common Stock
AU$58k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-41%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Net Issuance of Common Stock
AU$24m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Net Issuance of Common Stock
AU$16.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Net Issuance of Common Stock
AU$15.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Cochlear Ltd
Glance View
Cochlear Ltd. is a pioneering Australian company at the forefront of innovative hearing solutions, dedicated to transforming the lives of individuals with hearing loss. Founded in 1981, the company specializes in the development and manufacture of advanced cochlear implants, which are electronic devices that bypass damaged hair cells in the cochlea and stimulate the auditory nerve directly, enabling patients to perceive sound. With a global footprint, Cochlear serves a diverse range of customers, from newborns to adults, and its products are supported by a robust body of clinical evidence and state-of-the-art technology. As a leader in the industry, Cochlear has established strong relationships with healthcare professionals and patients alike, creating a loyal customer base that drives long-term growth. For investors, Cochlear presents a compelling opportunity in the healthcare sector, characterized by its relentless focus on research and development, which ensures a pipeline of innovative products that keep it ahead of competitors. The company’s financial performance has shown resilience, with steady revenue growth and a solid margin due to its unique position in the global market, coupled with a diversified revenue model that includes both product sales and ongoing service agreements. As the global population ages and awareness of hearing loss increases, Cochlear is well positioned to capitalize on the growing demand for its products. With a commitment to sustainability and corporate responsibility, Cochlear not only seeks to enhance shareholder value but also strives to make a meaningful impact on the lives of those with hearing difficulties, aligning its business success with social good.
See Also
What is Cochlear Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-45.6m
AUD
Based on the financial report for Jun 30, 2024, Cochlear Ltd's Net Issuance of Common Stock amounts to -45.6m AUD.
What is Cochlear Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
-13%
Over the last year, the Net Issuance of Common Stock growth was -13%.
You don't have any saved screeners yet
